These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31008077)

  • 1. Authoring a periodic adverse drug experience report…here's what you need to know!
    Kulkarni TN; Kulkarni NG
    Perspect Clin Res; 2019; 10(2):95-99. PubMed ID: 31008077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using resources for scientific-driven pharmacovigilance: from many product safety documents to one product safety master file.
    Furlan G
    Drug Saf; 2012 Aug; 35(8):615-22. PubMed ID: 22788233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports.
    Jullian S; Jaskiewicz L; Pfannkuche HJ; Parker J; Lalande-Luesink I; Lewis DJ; Close P
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):971-9. PubMed ID: 26175055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E2C(R2) Periodic Benefit-Risk Evaluation Report and E2C(R2) Periodic Benefit-Risk Evaluation Report--Questions and Answers; International Council for Harmonisation; Guidances for Industry; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Jul; 81(138):46938-40. PubMed ID: 27459749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance in pharmaceutical companies: An overview.
    Mammì M; Citraro R; Torcasio G; Cusato G; Palleria C; di Paola ED
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S33-7. PubMed ID: 24347978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety monitoring of cell-based medicinal products (CBMPs)].
    Funk MB; Frech M; Spranger R; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring product safety in the postmarketing environment.
    Sharrar RG; Dieck GS
    Ther Adv Drug Saf; 2013 Oct; 4(5):211-9. PubMed ID: 25114782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals.
    Ebbers HC; Mantel-Teeuwisse AK; Sayed-Tabatabaei FA; Moors EH; Schellekens H; Leufkens HG
    Eur J Clin Pharmacol; 2013 Feb; 69(2):217-26. PubMed ID: 22706615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process.
    Loder EW; Rayhill M; Burch RC
    Headache; 2018 Nov; 58(10):1639-1657. PubMed ID: 30367818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicinal Product Regulation: Portugal׳s Framework.
    Herdeiro MT; Bastos PD; Teixeira-Rodrigues A; Roque F
    Clin Ther; 2016 Sep; 38(9):2118-2126.e2. PubMed ID: 27574988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Internet and drug safety: what are the implications for pharmacovigilance?
    Cobert B; Silvey J
    Drug Saf; 1999 Feb; 20(2):95-107. PubMed ID: 10082068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interpretation of Guidelines on Good Pharmacovigilance Practices for European Union].
    Xie YM; Tian F
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2963-8. PubMed ID: 24471312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Conference on Harmonisation; guidance on Addendum to E2C Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(24):5551-2. PubMed ID: 14968802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.